Ocata Therapeutics Inc fka OCAT

[rocky301]

fwiw,

Once again, this topic points out others are in the game, although many are not at the brink of trials as ACT is, but always noteworthy to say the least.

Because ACT's money maker trial is dry AMD I try and follow those working towards the same. CellCure(BioTime subsidiary)is developing OpRegen for dry AMD and when TEVA(top 15 Pharma in size) took out an option to develop and commercialize this product last fall it spurred me to ask many questions of Biotime, Teva and CellCure and nothing would indicate to me they need to license a patented technique from ACT or purchase ACT cell lines in pursuing trials.
All of the following are exclusive to CellCure also.
http://escellinternational.co/property.htm